APA (7th ed.) Citation

Schneider, B. J., Shah, M. A., Klute, K., Ocean, A., Popa, E., Altorki, N., . . . Scandura, J. M. (2017). Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clinical cancer research, 23(11), 2673-2680. https://doi.org/10.1158/1078-0432.CCR-16-1896

Chicago Style (17th ed.) Citation

Schneider, Bryan J., et al. "Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response." Clinical Cancer Research 23, no. 11 (2017): 2673-2680. https://doi.org/10.1158/1078-0432.CCR-16-1896.

MLA (9th ed.) Citation

Schneider, Bryan J., et al. "Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response." Clinical Cancer Research, vol. 23, no. 11, 2017, pp. 2673-2680, https://doi.org/10.1158/1078-0432.CCR-16-1896.